Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Rise of Mid-Sized Pharma
2.
Contract Research Annual Review 2008
3.
Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023
4.
The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023
5.
Monoclonal Antibodies Report: 2008 Update
6.
Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players
7.
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
8.
Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch
9.
Drug Repositioning Strategies - Serendipity by design
10.
Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses
Best Sellers:
1.
BioNewsCast Press Release Distribution Service
2.
Immunogenicity to Biologics Implications of reactions against biotech drugs
3.
Outsourcing in Drug Discovery, 3rd Edition
4.
American Hospital Register
5.
Professional Designation in Biopharmaceutical Technology - 3 Course Curriculum
6.
Outlook for RNAi, 2007 - siRNA and miRNA in biology, diagnostics and therapeutics
Canadian Pharmaceutical Sales Management (PH107)
In Canada, access to physicians remains one of the top problems of the day for pharmaceutical sales organizations. Though not nearly as overrun as US doctors, top prescribing Canadian physicians can still expect to see as many as 4 to 6 different reps from some larger companies during a given month.
Combining access issues with stringent self-imposed and government regulations on how reps can sell their products and companies are scrambling to develop new and innovative sales strategies and tactics to stand out in a crowded market.
As the industry continues to evolve in the age of reduced access, patent expiry, generic incursion and slow pipelines, executives who focus resources on key strategic points now while effectively managing their sales forces will outpace their competition.
Cutting Edge Informations report Canadian Pharmaceutical Sales Management analyzes present trends to provide the steps pharmaceutical sales managers must take to stay competitive and beat the market. The report makes its case with metrics and techniques for managing all three aspects of the current sales landscape:
* Investment, Structure and Management Provides up-to-date investment levels, structuring strategies, and territory management of major pharma sales forces
* Sales Management Strategies Details companies strategies regarding recruiting, hiring, training, and sales team compensation
* In-Field Tactics Describes real-world maneuvers designed to increase access to physicians and make the most of face-to-face time with targets
Sample Content
Excerpt from Chapter 3 (In-Field Tactics) of Canadian Pharmaceutical Sales Management
Targeting
With the hopes of optimizing prescription growth within each reps territory, companies have not only struggled to determine what the most relevant metrics are to consider in segmenting physicians, but also to find out the magic number of visits needed to best influence their physicians prescribing behavior.
Interviews reveal that frequency of visits may be declining in the largest of pharmaceutical companies and increasing in smaller companies. Companies are trying to discover the magic number of visits to each tier of prescribers without reaching so high that reps annoy doctors or so low that competitors products win out.
As the sampling of pharmaceutical companies shows in Figure 3.5 and Figure 3.6 [figures appear in full report], the number of times reps visit their targets varies by their relative value. Those doctors considered to be high prescribers receive more visits on average from primary care reps and specialty reps than do mid- or low-level targets. On average, primary care reps visit their top targets 1.6 times per month, while visiting mid-level physicians an average of 0.8 times per month and low-level targets 0.5 times per month.
Specialty/Hospital reps visit their top targets an average of 1.7 times per month, their mid-level targets 1.0 times per month and low-level targets 0.6 times per month.
Published 2007
151 Pages
200+ Metrics
75+ Charts and Diagrams
Format PDF
Table of Contents
Price: $7,695.00 / GBP3,847.50
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.